Department of Pathology and Medicine, Stanford University, Stanford, California.
Department of Cardiology, Heart Failure Program, Bellvitge University Hospital and Biomedical Research Institute, Hospitalet de Liobregat, Barcelona, Spain.
Am J Hematol. 2017 Jan;92(1):88-93. doi: 10.1002/ajh.24595. Epub 2016 Dec 7.
Anemia is an independent risk factor for adverse patient outcomes. There are no guidelines for management of anemia in patients with congestive heart failure (CHF), despite its high incidence. Four objectives were defined by the International Anemia Management and Clinical Outcomes Expert Panel (AMCO), a multinational group of interdisciplinary experts identified by the Society for the Advancement of Blood Management (SABM) to: determine the prevalence of anemia in outpatients; to determine the prevalence of hospital-acquired anemia; to assess the impact of anemia management on clinical outcomes such as quality of life and functional status; and to provide recommendations for primary care physicians and specialists for the diagnosis, evaluation, and management of anemia in patients with CHF. Anemia and iron deficiency were confirmed to be highly prevalent in patients with CHF. Intravenous iron therapy improves anemia, cardiac function and exercise tolerance, leading to improvement in quality of life. Anemia management has been demonstrated to be cost-effective. Clinical care pathways to manage anemia in patients with CHF are recommended as best practices in order to improve patient outcomes. Am. J. Hematol. 92:88-93, 2017. © 2016 Wiley Periodicals, Inc.
贫血是影响患者预后的独立危险因素。尽管充血性心力衰竭（CHF）患者贫血的发病率很高，但目前尚无针对此类患者贫血管理的指南。国际贫血管理和临床结局专家组（AMCO）由 4 个目标组成，该专家组是一个多学科的跨国专家小组，由促进血液管理协会（SABM）确定，旨在：确定门诊患者贫血的患病率；确定医院获得性贫血的患病率；评估贫血管理对临床结局的影响，如生活质量和功能状态；并为初级保健医生和专家提供诊断、评估和管理 CHF 患者贫血的建议。贫血和缺铁在 CHF 患者中被证实是高度普遍存在的。静脉铁治疗可改善贫血、心功能和运动耐量，从而提高生活质量。贫血管理已被证明具有成本效益。建议采用治疗 CHF 患者贫血的临床护理路径作为最佳实践，以改善患者的预后。美国血液学杂志 92：88-93，2017。© 2016 威利父子出版公司
